Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mycobacteriology and Aerobic Actinomycetes

Integrating the Xpert MTB/RIF Assay into a Diagnostic Workflow for Rapid Detection of Mycobacterium tuberculosis in a Low-Prevalence Area

Vanessa Deggim, Akos Somoskovi, Antje Voit, Erik C. Böttger, Guido V. Bloemberg
Vanessa Deggim
aInstitut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland
bNationales Zentrum für Mykobakterien, Universität Zürich, Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akos Somoskovi
aInstitut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland
bNationales Zentrum für Mykobakterien, Universität Zürich, Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antje Voit
aInstitut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik C. Böttger
aInstitut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland
bNationales Zentrum für Mykobakterien, Universität Zürich, Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guido V. Bloemberg
aInstitut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.00151-13
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The Xpert MTB/RIF assay is a rapid and fully automated real-time PCR assay. The performance of the Xpert MTB/RIF assay as a primary screening test for urgent clinical specimens was evaluated during a 2-year period. The results showed that replacing smear microscopy with the Xpert MTB/RIF assay facilitates laboratory handling and improves the sensitivity and specificity of Mycobacterium tuberculosis detection.

TEXT

Rapid and accurate diagnosis of tuberculosis (TB) is indispensable to adequately manage the disease and control its transmission. Acid-fast bacilli (AFB) smear microscopy is an established low-cost screening procedure to identify patients with tuberculosis. However, the sensitivity of smear microscopy is low, varying between 22 and 80% (1). In general, the routine application of nucleic acid amplification techniques for detection of Mycobacterium tuberculosis results in accurate diagnosis of tuberculosis (2, 3, 4, 5, 6) but requires laborious processing time and dedicated biosafety conditions. The recently introduced Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is a fully automated, walk-away real-time PCR-based assay with a time to result of approximately 2 h. To detect M. tuberculosis and mutations associated with resistance to rifampin (RIF), the 81-bp core region of the rpoB gene is amplified and probed with five overlapping molecular beacons (7). M. tuberculosis is identified when at least 2 probes give a positive signal within a predefined number of cycles. A RIF mutation is detected by lack of or delayed onset of fluorescence of at least one molecular beacon. Disadvantages of the Xpert MTB/RIF are its exceeding costs and a reduced sensitivity in comparison with other PCR M. tuberculosis assays (8, 9).

The objective of the present study was to evaluate the feasibility of the Xpert MTB/RIF assay to replace direct smear microscopy as a primary screening test for urgent clinical specimens in a setting of low TB prevalence.

The Institute of Medical Microbiology (University of Zurich) is a tertiary care diagnostic center that receives clinical specimens 7 days/week for AFB microscopy to urgently confirm or rule out TB in newly identified suspect cases. Such samples are marked as urgent cases and are not to be confused with regular samples submitted to the mycobacteriology laboratory. All respiratory and nonrespiratory specimens submitted for urgent smear microscopy between July 2010 and June 2012 were included in this study; ethical approval was not needed. Specimens were adjusted to 5 ml with sterile distilled water when the specimen volume was <5 ml. The Xpert MTB/RIF assay was performed following the manufacturer's instructions for respiratory specimens, using a 1-ml aliquot. Nonrespiratory specimens were tested similarly. The remaining 4 ml of all unprocessed specimen with the exception of cerebrospinal fluid (CSF) was homogenized and decontaminated using an equal volume of N-acetyl-l-cysteine (NALC)–2% NaOH for 15 min (10). After neutralization with phosphate buffer (67 mM, pH 6.8) and centrifugation, the resuspended sediment was used to prepare auramine-rhodamine-stained smears and to inoculate MGIT 960 liquid (Becton, Dickinson, Towson, MD) and Middlebrook 7H11 culture media for growth detection. Positive auramine-rhodamine microscopy results were confirmed by Ziehl-Neelsen staining for specificity. AFB growth-positive cultures were identified by 16S rRNA gene sequence analysis as described previously (11, 12, 13). Further differentiation within the M. tuberculosis complex (MTC) was achieved using the Genotype MTBC line probe assay (LPA; Hain Lifescience GmbH, Nehren, Germany). Phenotypic drug susceptibility testing (DST) of MTC isolates was performed using the Bactec MGIT 960 system (Becton, Dickinson, Towson, MD) (14). A line probe assay (AID Analytika, Strasburg, Germany) was performed on the processed sediment of a subset of Xpert MTB/RIF-positive specimens to confirm molecular drug resistance results for rifampin (RIF) according to the manufacturer's instructions. Alternative nucleic acid amplification testing for detection of M. tuberculosis with the Cobas TaqMan MTB test (Roche Diagnostics, Rotkreuz, Switzerland) was carried out in parallel on specimen sediments.

In total, 71 respiratory and 8 nonrespiratory specimens were tested with the Xpert MTB/RIF assay in a prospective fashion (Tables 1 and 2). The Xpert MTB/RIF assay was positive for M. tuberculosis in 17 (21.5%) specimens and negative for M. tuberculosis in 60 (76%) specimens. The test was invalid or did not provide a result for M. tuberculosis detection in 2/79 (2.5%) specimens (1 sputum and 1 biopsy specimen). Both were smear negative and culture negative (Table 2, specimens 24 and 25). The biopsy specimen gave no Xpert MTB/RIF result due to a negative internal control, suggesting that the specimen contained PCR inhibitors.

View this table:
  • View inline
  • View popup
Table 1

Xpert MTB/RIF versus AFB smear microscopy and culture results for 79 clinical specimensa

View this table:
  • View inline
  • View popup
Table 2

Comparison of the Xpert MTB/RIF assay with culture identification and phenotypic RIF susceptibility testing for specimens positive or indeterminate for mycobacteria by culture or Xpert assay (n = 29)

Fourteen of the 17 Xpert M. tuberculosis-positive specimens were smear positive, and 3/17 were smear negative (Tables 1 and 2). Growth detection confirmed the presence of M. tuberculosis in all 14 smear-positive specimens and in 1 of 3 smear-negative specimens. One of the culture- and smear-negative specimens (Table 2, specimen 8) was a sputum sample from a patient with miliary tuberculosis following intravesical Mycobacterium bovis BCG instillation therapy for urine bladder cancer. This sample scored “MTB detected very low” by the Xpert MTB/RIF assay but scored negative by the Cobas TaqMan MTB assay, presumably due to specimen inhomogeneity. The second culture- and smear-negative sputum sample (Table 2, specimen 12) originated from a patient undergoing antituberculosis treatment, which may have limited the detection of viable mycobacteria by growth detection. This sample was confirmed M. tuberculosis positive by the Cobas TaqMan MTB assay.

Within the 60 Xpert MTB/RIF-negative specimens, 7 specimens (11.7%) yielded nontuberculous mycobacteria (NTM) by culture (3 Mycobacterium vulneris, 2 Mycobacterium avium, 1 Mycobacterium kansasii, and 1 Mycobacterium chimaera; all respiratory specimens). Five of these 7 specimens with NTM were smear positive.

The Xpert MTB/RIF correctly identified M. tuberculosis in all 14 smear-positive and culture MTC-positive specimens and ruled out tuberculosis in the 5 smear-positive specimens that grew NTM. These results indicate that the Xpert MTB/RIF is a better prescreening tool than smear microscopy, since it reliably identifies the presence of M. tuberculosis in patients with a high bacterial load and differentiates these from patients with NTM. This is especially relevant in our setting, since 26.3% (5/19) of smear-positive specimens in this study contained NTM and approximately 49% of all molecularly identified mycobacterial cultures in our laboratory during 2011 and 2012 contained NTM.

Cultures were MTC positive in 3/60 Xpert MTB/RIF-negative samples (Table 2; 1 cerebrospinal fluid specimen [number 26] and 1 ascitic fluid specimen [number 27], both with Mycobacterium africanum, and 1 pleural fluid specimen [number 28] with M. tuberculosis). All were smear negative. MGIT liquid culture was positive for all three samples, whereas 7H11 solid culture was only positive for the pleural fluid specimen. Previous studies showed a sensitivity of the Xpert MTB/RIF assay that varied between 46 and 77% in smear-negative and culture-positive specimens (7, 8, 15, 16, 17, 18). In our low-prevalence setting, the number of smear-negative and culture MTC-positive cases was low (1 respiratory and 3 nonrespiratory specimens). The Xpert MTB/RIF system correctly detected M. tuberculosis in one respiratory specimen, but it missed all 3 nonrespiratory specimens (ascites, pleural fluid, and CSF specimens). This indicates that nonrespiratory specimens may not be suitable for Xpert MTB/RIF testing, in particular for paucibacillary samples.

Conventional drug susceptibility testing (DST) did not reveal any drug resistance among the 18 cultured MTC isolates, while the Xpert MTB/RIF test indicated the presence of rpoB mutations associated with RIF resistance in 2 primary respiratory specimens. Repeated conventional DST and molecular discrepancy analysis by line probe assay and sequencing of the rpoB gene did not confirm RIF resistance in these specimens. Consequently, the Xpert MTB/RIF result for RIF resistance was scored as a false positive in these specimens (Table 2, specimens 10 and 11). The performance of the Xpert MTB/RIF assay to detect RIF resistance was not evaluated in this study, due to the absence of RIF-resistant MTC isolates. Nevertheless, as described earlier (19), we identified false RIF resistance by using the Xpert MTB/RIF assay for two respiratory specimens. These results have a significant impact on accurate screening for RIF resistance in a setting of low TB and low multidrug-resistant TB prevalence, such as Switzerland. As a consequence, we strongly recommend that in such settings Xpert MTB/RIF assay results indicating RIF resistance always be confirmed by an alternative molecular assay until conventional DST is available (20).

In conclusion, despite its limitations, e.g., its limited suitability for paucibacillary nonrespiratory samples, our results provide strong evidence that for respiratory samples in a low-prevalence setting, the Xpert MTB/RIF assay improves accurate primary screening and is well suited to replace smear microscopy for urgent specimens. The high costs of the Xpert MTB/RIF assay could be compensated by its fast and walk-away methodology compared to the laborious procedure of AFB microscopy, which involves tedious reading of slides and well-experienced personnel for high-quality results.

ACKNOWLEDGMENTS

This work was supported in part by the University of Zurich and the BAG (Federal Office of Public Health, Switzerland).

We have no conflicts of interest to disclose.

FOOTNOTES

    • Received 17 January 2013.
    • Returned for modification 26 February 2013.
    • Accepted 17 April 2013.
    • Accepted manuscript posted online 24 April 2013.
  • Copyright © 2013, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Steingart KR,
    2. Ramsay A,
    3. Pai M
    . 2007. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev. Anti Infect. Ther. 5:327–331.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Böddinghaus B,
    2. Rogall T,
    3. Flohr T,
    4. Blöcker H,
    5. Böttger EC
    . 1990. Detection and identification of mycobacteria by amplification of rRNA. J. Clin. Microbiol. 28:1751–1759.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Kirschner P,
    2. Rosenau J,
    3. Springer B,
    4. Teschner K,
    5. Feldmann K,
    6. Böttger EC
    . 1996. Diagnosis of mycobacterial infections by nucleic acid amplification: 18-month prospective study. J. Clin. Microbiol. 34:304–312.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Reischl U,
    2. Lehn N,
    3. Wolf H,
    4. Naumann L
    . 1998. Clinical evaluation of the automated Cobas Amplicor MTB assay for testing respiratory and nonrespiratory specimens. J. Clin. Microbiol. 36:2853–2860.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Piersimoni C,
    2. Scarparo C
    . 2003. Relevance of commercial amplification methods for direct detection of Mycobacterium tuberculosis complex in clinical samples. J. Clin. Microbiol. 41:5355–5365.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Yang YC,
    2. Lu PL,
    3. Huang SC,
    4. Jenh YS,
    5. Jou R,
    6. Chang TC
    . 2011. Evaluation of the Cobas TaqMan MTB test for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J. Clin. Microbiol. 49:797–801.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Boehme CC,
    2. Nabeta P,
    3. Hillemann D,
    4. Nicol MP,
    5. Shenai S,
    6. Krapp F,
    7. Allen J,
    8. Tahirli R,
    9. Blakemore R,
    10. Rustomjee R,
    11. Milovic A,
    12. Jones M,
    13. O'Brien SM,
    14. Persing DH,
    15. Ruesch-Gerdes S,
    16. Gotuzzo E,
    17. Rodrigues C,
    18. Alland D,
    19. Perkins MD
    . 2010. Rapid molecular detection of tuberculosis and rifampicin resistance. N. Engl. J. Med. 363:1005–1015.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Armand S,
    2. Vanhuls P,
    3. Delcroix G,
    4. Courcol R,
    5. Lemaître N
    . 2011. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J. Clin. Microbiol. 49:1772–1776.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Teo J,
    2. Jureen R,
    3. Chiang D,
    4. Chan D,
    5. Lin R
    . 2011. Comparison of two nucleic acid amplification assays, the Xpert MTB/RIF assay and the amplified Mycobacterium tuberculosis Direct assay, for detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J. Clin. Microbiol. 49:3659–3662.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Kent PT,
    2. Kubica GP
    . 1985. Public health mycobacteriology: a guide for level III laboratory. Centers for Disease Control, Atlanta, GA.
  11. 11.↵
    1. Rogall T,
    2. Flohr T,
    3. Böttger EC
    . 1990. Differentiation of Mycobacterium species by direct sequencing of amplified DNA. J. Gen. Microbiol. 136:1915–1920.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Kirschner P,
    2. Springer B,
    3. Vogel U,
    4. Meier A,
    5. Wrede A,
    6. Kiekenbeck M,
    7. Bange FC,
    8. Böttger EC
    . 1993. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory. J. Clin. Microbiol. 31:2882–2889.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Springer B,
    2. Stockman L,
    3. Teschner K,
    4. Roberts GD,
    5. Böttger EC
    . 1996. Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. J. Clin. Microbiol. 34:296–303.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Springer B,
    2. Lucke K,
    3. Calligaris-Maibach R,
    4. Ritter C,
    5. Böttger EC
    . 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J. Clin. Microbiol. 47:1773–1780.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Helb D,
    2. Jones M,
    3. Story E,
    4. Boehme C,
    5. Wallace E,
    6. Ho K,
    7. Kop J,
    8. Owens MR,
    9. Rodgers R,
    10. Banada P,
    11. Safi H,
    12. Blakemore R,
    13. Ngoc Lan NT,
    14. Jones-López EC,
    15. Levi M,
    16. Burday M,
    17. Ayakaka I,
    18. Mugerwa RD,
    19. McMillan B,
    20. Winn-Deen E,
    21. Christel L,
    22. Dailey P,
    23. Perkins MD,
    24. Persing DH,
    25. Alland D
    . 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48:229–237.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Boehme CC,
    2. Nicol MP,
    3. Nabeta P,
    4. Michael JS,
    5. Gotuzzo E,
    6. Tahirli R,
    7. Gler M,
    8. Blakemore R,
    9. Worodria W,
    10. Gray C,
    11. Huang L,
    12. Caceres T,
    13. Mehdiyev R,
    14. Raymond L,
    15. Whitelaw A,
    16. Sagadevan K,
    17. Alexander H,
    18. Albert H,
    19. Cobelens F,
    20. Cox H,
    21. Alland D,
    22. Perkins MD
    . 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:1495–1505.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Theron G,
    2. Peter J,
    3. van Zyl-Smit R,
    4. Mishra H,
    5. Streicher E,
    6. Murray S,
    7. Dawson R,
    8. Whitelaw A,
    9. Hoelscher M,
    10. Sharma S,
    11. Pai M,
    12. Warren R,
    13. Dheda K
    . 2011. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am. J. Respir. Crit. Care Med. 184:132–140.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Moure R,
    2. Muñoz L,
    3. Torres M,
    4. Santin M,
    5. Martín R,
    6. Alcaide F
    . 2011. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J. Clin. Microbiol. 49:1137–1139.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Zbinden A,
    2. Keller PM,
    3. Bloemberg GV
    . 2011. Comment on “Rapid molecular detection of tuberculosis and rifampin resistance”. N. Engl. J. Med. 364:183. (Reply, 364:184–185.)
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Somoskovi A,
    2. Parsons LM,
    3. Gutierrez C,
    4. Lee E,
    5. Salfinger M
    . 2012. Line probe and automated real-time PCR TB assays warrant adherence to strict quality assurance measures. Int. J. Tuberc. Lung Dis. 16:705–706.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Integrating the Xpert MTB/RIF Assay into a Diagnostic Workflow for Rapid Detection of Mycobacterium tuberculosis in a Low-Prevalence Area
Vanessa Deggim, Akos Somoskovi, Antje Voit, Erik C. Böttger, Guido V. Bloemberg
Journal of Clinical Microbiology Jun 2013, 51 (7) 2396-2399; DOI: 10.1128/JCM.00151-13

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Integrating the Xpert MTB/RIF Assay into a Diagnostic Workflow for Rapid Detection of Mycobacterium tuberculosis in a Low-Prevalence Area
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Integrating the Xpert MTB/RIF Assay into a Diagnostic Workflow for Rapid Detection of Mycobacterium tuberculosis in a Low-Prevalence Area
Vanessa Deggim, Akos Somoskovi, Antje Voit, Erik C. Böttger, Guido V. Bloemberg
Journal of Clinical Microbiology Jun 2013, 51 (7) 2396-2399; DOI: 10.1128/JCM.00151-13
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X